semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sickle Cell Disease Pain FOR CELL All subjects with sickle cell disease will be eligible for enrollment in this study if they meet all of the following 18 years of age or older Diagnosis of sickle cell disease (electrophoretic or HPLC documentation of hemoglobin S only phenotype is required) No vaso-occlusive crisis during the previous two weeks Medically stable Can speak and understand English to complete assessments and scales FOR All volunteer matched control study participants will be eligible for enrollment on this study if they meet all the following 18 years of age or older Non-sickle cell trait or disease Medically healthy based upon the history and physical exam and screening blood analyses No chronic pain condition. Can speak and understand English to complete assessments and scales Ethnicity, age (within 5 years), and sex matched to that of sickle cell subjects already enrolled on study  FOR ALL STUDY Study participants will be excluded from the study if he/she has one or more of the following: Inability to provide his/her own informed consent. Drug or alcohol dependence/abuse within the past 5 years Cigarette smoking or the use of any tobacco products within two years Use of tranquilizers, steroids, non-steroidal anti-inflammatory agents three or more times per week. Clinically significant medical condition that will confound the analysis of factors associated with sickle cell pain, such as Chronic inflammatory disease (i.e. rheumatoid arthritis, systemic lupus erythematosus, cirrhosis) Diabetes mellitus Uncontrolled hypertension Known malignancies
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Coronary Syndrome Patients age 18 or older, of both genders 2. Presenting with an ACS, defined as at least two of the following symptoms consistent with myocardial ischemia ST segment elevation or depression of at least 1 mm in 2 or more contiguous leads on EKG a cardiac troponin I level above upper limit of normal. 3. Self-reported African-american or Caucasian race a. all 4 grandparents of same race 4. No contraindications to prasugrel therapy. 5. Patient is scheduled for, or has already undergone, PCI  Known allergies to aspirin, clopidogrel, or prasugrel. 2. Patient known to be pregnant or lactating. 3. Patient with known history of bleeding diathesis or currently active bleeding. 4. Platelet count <100,000/mm at the time of enrollment. 5. Hematocrit <25% at the time of enrollment. 6. On warfarin therapy at the time of PCI, or patient likely to require warfarin therapy post-PCI. 7. Received fibrinolytics within the past 48 hours. 8. Received a glycoprotein IIb/IIIa inhibitor within the past 48 hours, or if such a strategy for PCI involving a glycoprotein IIb/IIIa inhibitor is planned. 9. Taking maintenance thienopyridine therapy in the previous 5 days. 10. Known blood transfusion within the preceding 10 days. 11. Patients treated with non-steroidal anti-inflammatory drugs (NSAIDS) within the previous 5 days. 12. Patients with known chronic liver disease. 13. Age greater than 75 years 14. Body weight less than 60 kg 15. History of stroke or transient ischemic attack 16. Surgery planned within 1 month 17. Patient likely to require coronary artery bypass grafting 18. Any significant medical condition that, in the investigator's opinion, may interfere with the patient's optimal participation in the study
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Vitamin D Deficiency Chronic Pain Syndrome Inflammatory Response We enrolled patients suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months  Patients with low compliance Allergy for vit D
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 0.0-45.0,  Anemia, Sickle Cell Complex and Transfusion-dependent Hemoglobinopathies Thalassemia Diamond-Blackfan Anemia Bone Marrow Failure Syndromes Alpha-Thalassemia Beta-Thalassemia The following are established to identify subjects with hemoglobinopathies, hematologic or bone marrow failure syndromes who have a high predicted morbidity and are at risk for early mortality Patients with alpha or beta thalassemia major Patients with Diamond-Blackfan anemia and other bone marrow failure syndromes, characterized by severe chronic anemia Patients with other complex and transfusion-dependent hemoglobinopathies, including sickle cell disease Patients with sickle disease who have one or more of the following Overt or silent stroke Neurocognitive impairment Pain crises 2 or more episodes per year for past year One or more episodes of acute chest syndrome Osteonecrosis involving 1 or more joints  Patients with cirrhosis, extensive bridging hepatic fibrosis, or active hepatitis are excluded from enrollment Uncontrolled infection or severe concomitant diseases, which in the judgment of the Principal Investigator, indicate that the patient could not tolerate reduced intensity transplantation Severe impairment of functional performance as evidenced by a Karnofsky score <70% (patients ≥16 years old) or Lansky (children <16 years old) score <70% Renal insufficiency (GFR <50 ml/min/1.73 m2) Subjects with a positive human immunodeficiency virus (HIV) antibody test result Subjects who are pregnant, as indicated by a positive serum human chorionic gonadotrophin (HCG) test Subjects whose only donor is pregnant at the time of intended transplant Subjects of childbearing potential who are not practicing adequate contraception as defined by the investigator at the site Allogeneic hematopoietic stem cell transplant within the previous 1 year Subjects must not have had previous radiation therapy that would preclude total body irradiation (TBI) (as determined by a radiation therapist)
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sickle Cell Disease Vaso-occlusive Crisis Documented HgbSS or HgbS-beta0 thalassemia by previous hemoglobin electrophoresis age greater than 18 years old, and admit diagnosis of vaso-occlusive crisis. Labs must be drawn within 36 hours of admission and randomization to treatment arm must occur during this time  End stage renal disease (creatinine >3.0 mg/dL) use of antiplatelet or anticoagulation medication for an alternative indication use of steroids or immunosuppressive medications platelet count less than 100 X 109/L history or development of heparin induced thrombocytopenia, packed red blood cell transfusion in the past one month, or recent hospitalization with discharge within the past 1 week. Patients with re-admissions will not be enrolled again and will have no further samples drawn
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Male and female subjects ≥ 18 years of age with moderate to severe, chronic low back pain (lasting at least several hours daily) as their predominant pain condition for at least 3 months prior to screening period The low back pain must be related to nonmalignant and nonneuropathic conditions and may be with or without radiation Subjects must have a self-reported history of opioid induced constipation (OIC)  Subjects with rheumatoid arthritis or other inflammatory arthritis Subjects with neuropathic conditions that have been painful or required therapy within the past 3 months Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract or other significant conditions affecting GI motility Subjects with chronic constipation not related to opioid use Subjects who had surgical procedures directed towards the source of chronic low back pain within 6 months of the screening visit or planned during the study Subjects with a history of malignancy within the past 2 years, with the exception of basal cell carcinoma that has been successfully treated. Other protocol specific inclusion/
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain Male and female subjects ≥ 18 years of age with moderate to severe, chronic low back pain (lasting at least several hours daily) as their predominant pain condition for at least 3 months prior to screening period The low back pain must be related to nonmalignant and nonneuropathic conditions and may be with or without radiation Subjects must have a self-reported history of opioid induced constipation (OIC)  Subjects with rheumatoid arthritis or other inflammatory arthritis Subjects with neuropathic conditions that have been painful or required therapy within the past 3 months Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract or other significant conditions affecting GI motility Subjects with chronic constipation not related to opioid use Subjects who had surgical procedures directed towards the source of chronic low back pain within 6 months of the screening visit or planned during the study Subjects with a history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated. Other protocol specific inclusion/
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pain Constipation Subjects who are receiving WHO step III opioid analgesic medication for the treatment of non-malignant or malignant pain Documented history of non-malignant or malignant pain that requires around-the-clock opioid therapy  Females who are pregnant or lactating Subjects with evidence or significant structural abnormalities of the gastrointestinal tract Subjects with evidence of impaired liver/kidney function upon entry into the study
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Genotype Pain Genetic Variation Quantitative Sensory Testing (QST) GCH1 FOR ALL All study participants must be of self-described African or African American ancestry. They will be at least 18 years old and must be able to provide informed, written consent for participation. for Sickle Cell Patients 1. Diagnosis of sickle cell disease (documentation of SS, SC, S beta + thalassemia, S beta + thalassemia by electrophoresis is required). 2. If taking chronic analgesics (NSAID, acetaminophen) or opioids, study subjects should be on a stable dose for 4 weeks prior to recruitment. for Control Subjects 1. Hemoglobin AA genotype by HPLC or hemoglobin electrophoresis. 2. General good health defined as the absence of untreated major medical conditions (e.g. uncontrolled systemic hypertension, etc.)  for Sickle Cell Patients 1. History of severe vaso-occlusive pain crisis resulting in either evaluation in an emergency department or admission to a hospital during the two weeks prior to study enrollment. 2. Acute pain at the time of enrollment defined as spontaneous recent onset pain with a self rated score of 6 or higher on a scale of 0-10. (This is acute pain not the pain that subjects function at on a daily basis.) for Control Subjects 1. Acute pain or injury at enrollment or a recent history of chronic pain (daily pain reported for at least 6 months) in the past 3 years. 2. Major medical/psychiatric illness known to cause pain. 3. Sickle cell trait
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Sickle Cell Anemia Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype 2. Patients ≥ 16 years of age 3. Patients with ≥ 6 months of follow-up data available from first SCD treatment at the center after they reach 16 years old 4. At least one SF reading during a non-acute phase on or after the first SCD treatment at the center after they reach 16 years old  Patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for SCD (1) within the six months before the index date or (2) during the patient observation period 2. Patients with sickle cell trait Other protocol-defined inclusion/
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Back Pain Consent of the patient or legal guardian Men or women aged between 18 and 65 Diagnosis of acute low back pain with moderate to severe pain (Visual Analogic score greater than 4 cm)  fracture confirmed by X-ray Diagnosis of infection, fever Pregnancy, lactation Diagnosis of fibromyalgia Hypersensitivity to ketorolac tromethamine, any of the ingredients of the formula or other Nonsteroidal anti-inflammatory